The popularity of Sildenafil initially drove a period of growth for pharma, however recent shifts present a uncertain picture for investors. Lower-cost alternatives are eroding revenue, and persistent patent challenges https://katrinawidr412161.bloggip.com/41598492/sildenafil-and-the-pharmaceutical-industry-a-precarious-bet